A Phase 1/2 interventional study of AGEN2034 in Advanced Cancer and Cervical Cancer, sponsored by Agenus Inc.. Completed at 44 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by Agenus Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 145 open to participants now, 219 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 183rd largest by enrollment of the 678 interventional ones that give a count, is one of 26 that started in 2017, is one of 74 in phase 1/2, and was the 429th registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.
Browse Uterine Cervical Neoplasms studies →145 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 30–65 · Women only · Healthy volunteers
Florida A&M University · Sites in United States
Ages 21–65 · Women only · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
Mark Bernard · Sites in United States
Ages 18–99
University of Florida · Sites in United States
Ages 25+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
834 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 242 · Phase 2 240 · Phase 3 45 · Phase 4 9
First in 1992; this study’s year is marked. 26 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 100 across 1,738 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 71 across the 678 interventional studies, 138 across the 124 observational. Of the 569 that completed or were terminated, 193 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 834 have an industry lead sponsor. The 10 most frequent:
Agenus Inc. is the lead sponsor of 31 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
Agenus Inc. has 5 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
87 of the studies in Uterine Cervical Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
| NCT05758688Abramson Cancer Center at Penn MedicinePROton Therapy for Post Surgical Treatment of GYNecologic Cancer | 2026-11 |
| NCT07574190University of South DakotaA Mobile Web App Intervention to Promote Cervical Cancer Screening | 2026-11 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
Add all 87 to your calendar (.ics) → With an account.
Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.
Phase 1: Dose Escalation
Phase 1 will consist of a standard 3+3 dose escalation with the following escalating dose levels and schedules:
Part A1: 1, 3, and 10 milligrams/kilogram (mg/kg) administered every 2 weeks
Part A2: 6 and 10 mg/kg every 3 weeks
Each participant will stay on the dose level and schedule assigned at trial entry. Participants will receive AGEN2034 for a maximum of 2 years or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.
A Safety Monitoring Committee (SMC) will assess safety; decide on dose-escalation and opening of backfill enrollment; define the recommended Phase 2 dose (RP2D); and determine opening of the Phase 2 cohorts.
In Part A1, the first participant of each cohort will be observed for 16 days (that is, ≥48 hours after second dose) for occurrence of dose-limiting toxicity (DLT) before the second participant is administered trial medication. Thereafter, within each cohort, consecutively enrolled participants may initiate treatment ≥48 hours after the prior enrolled participant-initiated treatment. Dose escalation will continue until the maximum tolerated dose (MTD) is reached or the maximum planned dose level (10.0 mg/kg) is shown to be safe. The MTD is defined as the dose below which ≥2 DLTs are observed.
Once Part A1 is completed, enrollment to Part A2 will begin. If \<2 DLTs are observed in Part A1 at the maximum planned dose of 10 mg/kg every 2 weeks, open enrollment to Part A2 will begin with enrollment of 10 participants at 6 mg/kg every 3 weeks, followed by open enrollment of 10 participants at 10 mg/kg every 3 weeks. If ≥2 DLTs are observed in Part A1, at the maximum planned dose in Part A1, the standard 3+3 dose escalation will resume with Part A2 where consecutively enrolled participants in dose escalation may initiate treatment ≥48 hours after the prior enrolled participant-initiated treatment.
For cohorts in dose escalation, concurrent with the 3+3 dose escalation schema, additional participants will be backfilled to lower dose levels to ensure that each cohort enrolls a total of 10 participants. Participants enrolled to backfill cohorts may be enrolled simultaneously, without sequential dosing (that is, not required to wait 48 hours between 2 participants). These additional participants at each dose level will have the purpose of generating additional safety, pharmacokinetics, and receptor occupancy data, and will not undergo formal DLT observation.
Phase 2: Dose Expansion
To further characterize safety and efficacy, participants with recurrent, unresectable, or metastatic cervical cancer will be enrolled in Phase 2 and receive the RP2D of AGEN2034 (3 mg/kg every 2 weeks) for a maximum of 2 years or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.
An SMC will assess safety, and an Independent Data Monitoring Committee will evaluate safety and efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis and prior systemic treatment:
- based on investigator assessment
Have adequate organ function as indicated by the following laboratory values:
In Phase 2, participants must provide a sufficient and adequate formalin-fixed paraffin-embedded tumor tissue sample preferably from the most recent biopsy of a tumor lesion, collected either at the time of or after the diagnosis of advanced or metastatic disease has been made and from a site not previously irradiated. If no tumor tissue is available, a fresh biopsy will be required.
Note: Tissue from needle or excisional biopsy or from resection is required.
Female participants must have a negative serum pregnancy test at screening (within 72 hours before first dose of study drug) if of or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons):
If of childbearing potential, female participants must be willing to use 2 highly effective methods (defined in the informed consent form [ICF]) throughout the study, starting with the screening visit through 120 days after the last dose of study treatment.
Note: Abstinence is acceptable if this is the established and preferred for the participant.
Male participants with a female partner(s) of childbearing potential must agree to use 2 highly effective methods (defined in the ICF) throughout the trial starting with the screening visit through 120 days after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
Note: Abstinence is acceptable if this is the established and preferred contraception for the participant.
Exclusion Criteria:
Has an inadequate prior to first dose of study drug defined as:
Has received prior therapy with:
Has persisting toxicity related to prior therapy of National Cancer Institute version 4.03 (NCI CTCAE) Grade >1 severity.
Note: Sensory neuropathy or alopecia of Grade ≤2 is acceptable.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose of 3 mg/kg intravenous (IV) every 2 weeks for up to 24 months.
Drug: AGEN2034
Anti-programmed cell death protein-1 (PD-1) Monoclonal Antibody
Also known as: Anti-PD-1
Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab
A DLT was defined as any treatment-related toxicity that was National Cancer Institute Common Terminology Criteria for Adverse Event Grade ≥3, confirmed by the safety monitoring committee to be relevant for the study drug treatment, and that occurred during the first 3 weeks of balstilimab treatment in the dose escalation portion of the study (DLT evaluation period).
Time frame: 21 days
Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious), regardless of causality, is located in the 'Reported Adverse Events' Section.
Time frame: Up to 3 years
Phase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC)
ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as determined by an IERC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 3 years
Phase 1: Receptor Occupancy of Circulating T Cells
The percentage of PD-1 receptor occupancy on circulating T cells was measured as an indication of target engagement. An increase in percent occupancy indicates a potential increase in drug effectiveness.
Time frame: 4 hours after the first dose (Cycle 1 Day 1) and immediately prior to the second dose (Cycle 2 Day 1) (2-3 weeks/cycle)
Phase 1: Maximum Observed Concentration (Cmax) of Balstilimab
Blood samples were collected for serum balstilimab concentration determinations. Results are reported as micrograms/milliliter (ug/mL).
Time frame: Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2-3 weeks/cycle) (up to 3 weeks)
Phase 1: Area Under the Drug Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of Balstilimab
Blood samples were collected for serum balstilimab concentration determinations. Results are reported as hours\*micrograms/milliliter (h\*µg/mL).
Time frame: Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2-3 weeks/cycle) (up to 3 weeks)
Phase 1: Number of Participants With Serum Anti-drug Antibodies (ADAs) for Balstilimab
Blood samples were collected for serum balstilimab ADA determination.
Time frame: Up to 2.5 years
Phase 2: Number of Participants Experiencing TEAEs
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to 3 years
Phase 2: Cmax of Balstilimab
Blood samples were collected for serum balstilimab concentration determinations. Results are reported in μg/mL.
Time frame: Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2 weeks/cycle) (up to 2 weeks)
Phase 2: AUC0-last of Balstilimab
Blood samples were collected for serum balstilimab concentration determinations. Results are reported in day\*μg/mL.
Time frame: Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2 weeks/cycle) (up to 2 weeks)
Phase 2: Number of Participants With Serum ADAs for Balstilimab
Blood samples were collected for serum balstilimab ADA determination.
Time frame: Up to 2.5 years
Phase 2: ORR as Determined by the Investigator
ORR was defined as percentage of participants with a BOR of CR or PR, as determined by the investigator per RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 3 years
Phase 2: Duration of Response (DOR)
DOR was defined as time from first observation of response to first observation of documented progressive disease (PD) (or death within 12 weeks after last tumor assessment), per RECIST 1.1 and as determined by an IERC and the investigator. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). Participants without an event at analysis cutoff date were censored on date of last tumor assessment.
Time frame: Up to 3 years
Phase 2: Disease Control Rate (DCR) as Determined by an IERC
DCR was defined as the percentage of participants with CR, PR, or stable disease (SD) for at least 12 weeks. CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).
Time frame: Up to 3 years
Phase 2: Tumor Control Rate (TCR) as Determined by an IERC
TCR was defined as percentage of participants who had a BOR of either SD or a confirmed objective response (CR or PR). CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).
Time frame: Up to 3 years
Phase 2: Time to Response (TTR) as Determined by an IERC
TTR was defined as the time from the first dose date to first observation of confirmed response.
Time frame: Up to 3 years
Phase 2: Progression-free Survival (PFS)
PFS was defined as time from first treatment administration to first observation of documented PD (or death within 12 weeks after last tumor assessment), per RECIST 1.1, as determined by an IERC and investigator. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). Participants without an event at analysis cutoff date were censored on date of last tumor assessment.
Time frame: Up to 3 years
Phase 2: Overall Survival (OS)
OS was defined as time from start of treatment to death. For participants who were still alive at the time of data cutoff for trial analysis or who were lost to follow-up, survival was censored at the last recorded date that the participant was known to have been alive as of the cutoff date for analysis.
Time frame: Up to 3 years
| Milestone | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 0 |
| Received at least 1 dose of study drug | 10 | 10 | 10 | 10 | 10 | 0 |
| Completed | 0 | 0 | 2 | 0 | 0 | 0 |
| Not completed | 10 | 10 | 8 | 10 | 10 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 4 | 8 | 4 | 0 |
| Withdrew: Physician decision | 0 | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Death | 6 | 3 | 0 | 1 | 1 | 0 |
| Withdrew: Completed follow up | 2 | 2 | 1 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 2 | 0 |
| Milestone | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 161 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 0 | 0 | 161 |
| Completed | 0 | 0 | 0 | 0 | 0 | 28 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 133 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 107 |
| Withdrew: Participant left to participate in another trial | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Administrative study closure | 0 | 0 | 0 | 0 | 0 | 13 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 1 |
A DLT was defined as any treatment-related toxicity that was National Cancer Institute Common Terminology Criteria for Adverse Event Grade ≥3, confirmed by the safety monitoring committee to be relevant for the study drug treatment, and that occurred during the first 3 weeks of balstilimab treatment in the dose escalation portion of the study (DLT evaluation period).
| Participants | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 |
|---|---|---|---|---|---|
| Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious), regardless of causality, is located in the 'Reported Adverse Events' Section.
| Participants | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 |
|---|---|---|---|---|---|
| Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | 10 | 10 | 10 | 10 | 10 |
ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as determined by an IERC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Phase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC) | 15.6 (10.8 to 22.0) |
The percentage of PD-1 receptor occupancy on circulating T cells was measured as an indication of target engagement. An increase in percent occupancy indicates a potential increase in drug effectiveness.
| percent occupancy | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 73.2 ± 11.95 | 69.4 ± 5.52 | — | 76.6 ± 2.95 | — |
| Cycle 2 Day 1 | 67.7 ± 16.93 | 61.6 ± 1.70 | — | 72.1 ± 8.29 | — |
Blood samples were collected for serum balstilimab concentration determinations. Results are reported as micrograms/milliliter (ug/mL).
| ug/mL | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 18.1 ± 34.3 | 71.9 ± 19.5 | 153 ± 23.7 | 236 ± 26.6 | 282 ± 28.4 |
| Cycle 2 Day 1 | 20.3 ± 47.0 | 86.3 ± 30.0 | 161 ± 27.5 | 239 ± 28.2 | 315 ± 25.5 |
Blood samples were collected for serum balstilimab concentration determinations. Results are reported as hours\*micrograms/milliliter (h\*µg/mL).
| h*µg/mL | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 1265 ± 47.4 | 6470 ± 34.6 | 12632 ± 51.5 | 22294 ± 47.5 | 30751 ± 50.4 |
| Cycle 2 Day 1 | 1477 ± 73.7 | 7725 ± 40.2 | 17479 ± 49.4 | 21298 ± 47.1 | 42266 ± 41.0 |
Blood samples were collected for serum balstilimab ADA determination.
| Participants | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 |
|---|---|---|---|---|---|
| Phase 1: Number of Participants With Serum Anti-drug Antibodies (ADAs) for Balstilimab | 3 | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Phase 2: Number of Participants Experiencing TEAEs | 161 |
Blood samples were collected for serum balstilimab concentration determinations. Results are reported in μg/mL.
| μg/mL | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Cycle 1 Day 1 | 55.4 ± 42.8 |
| Cycle 2 Day 1 | 56.6 ± 23.9 |
Blood samples were collected for serum balstilimab concentration determinations. Results are reported in day\*μg/mL.
| day*μg/mL | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Cycle 1 Day 1 | 174 ± 46.3 |
| Cycle 2 Day 1 | 184 ± 59.7 |
Blood samples were collected for serum balstilimab ADA determination.
| Participants | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Phase 2: Number of Participants With Serum ADAs for Balstilimab | 7 |
ORR was defined as percentage of participants with a BOR of CR or PR, as determined by the investigator per RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Phase 2: ORR as Determined by the Investigator | 14.4 (9.8 to 20.6) |
DOR was defined as time from first observation of response to first observation of documented progressive disease (PD) (or death within 12 weeks after last tumor assessment), per RECIST 1.1 and as determined by an IERC and the investigator. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). Participants without an event at analysis cutoff date were censored on date of last tumor assessment.
| months | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| IERC | NA (7.3 to NA) |
| Investigator | NA (8.9 to NA) |
DCR was defined as the percentage of participants with CR, PR, or stable disease (SD) for at least 12 weeks. CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).
| percentage of participants | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Phase 2: Disease Control Rate (DCR) as Determined by an IERC | 50.6 (43.0 to 58.3) |
TCR was defined as percentage of participants who had a BOR of either SD or a confirmed objective response (CR or PR). CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).
| percentage of participants | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Phase 2: Tumor Control Rate (TCR) as Determined by an IERC | 52.5 (44.8 to 60.1) |
TTR was defined as the time from the first dose date to first observation of confirmed response.
| days | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Phase 2: Time to Response (TTR) as Determined by an IERC | 82.0 (60.5 to 108.4) |
PFS was defined as time from first treatment administration to first observation of documented PD (or death within 12 weeks after last tumor assessment), per RECIST 1.1, as determined by an IERC and investigator. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). Participants without an event at analysis cutoff date were censored on date of last tumor assessment.
| months | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| IERC | 2.8 (2.4 to 3.9) |
| Investigator | 3.6 (2.7 to 4.2) |
OS was defined as time from start of treatment to death. For participants who were still alive at the time of data cutoff for trial analysis or who were lost to follow-up, survival was censored at the last recorded date that the participant was known to have been alive as of the cutoff date for analysis.
| months | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|
| Phase 2: Overall Survival (OS) | 11.2 (9.5 to 14.5) |
Collected over From Day 1 to the end of study (3 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Balstilimab Dose 1 | 6/10 (60%) | 5/10 (50%) | 10/10 (100%) |
| Phase 1: Balstilimab Dose 2 | 3/10 (30%) | 3/10 (30%) | 10/10 (100%) |
| Phase 1: Balstilimab Dose 3 | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Phase 1: Balstilimab Dose 4 | 1/10 (10%) | 3/10 (30%) | 10/10 (100%) |
| Phase 1: Balstilimab Dose 5 | 1/10 (10%) | 2/10 (20%) | 10/10 (100%) |
| Phase 2: Balstilimab Recommended Phase 2 Dose | 108/161 (67.1%) | 90/161 (55.9%) | 158/161 (98.1%) |
| Event | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|---|---|---|---|---|
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 | 2/161 |
| Metastases to spineNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 | 0/161 |
| Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 0/10 | 0/10 | 1/10 | 0/10 | 1/161 |
| Hypertensive crisisVascular disorders | 0/10 | 0/10 | 1/10 | 0/10 | 0/10 | 0/161 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/10 | 1/10 | 0/10 | 0/10 | 0/10 | 1/161 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 | 0/161 |
| Confusional statePsychiatric disorders | 0/10 | 1/10 | 0/10 | 0/10 | 0/10 | 0/161 |
| Cardiopulmonary failureCardiac disorders | 1/10 | 0/10 | 0/10 | 0/10 | 0/10 | 0/161 |
| Ischaemic strokeNervous system disorders | 0/10 | 0/10 | 1/10 | 0/10 | 0/10 | 0/161 |
| ColitisGastrointestinal disorders | 0/10 | 0/10 | 1/10 | 0/10 | 0/10 | 1/161 |
| Event | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 | Phase 2: Balstilimab Recommended Phase 2 Dose |
|---|---|---|---|---|---|---|
| Erectile dysfunctionReproductive system and breast disorders | 0/2 | 1/2 | 0/1 | 1/1 | 0/2 | — |
| FatigueGeneral disorders | 7/10 | 4/10 | 3/10 | 7/10 | 3/10 | 37/161 |
| AnaemiaBlood and lymphatic system disorders | 7/10 | 4/10 | 3/10 | 3/10 | 3/10 | 80/161 |
| NauseaGastrointestinal disorders | 6/10 | 3/10 | 4/10 | 5/10 | 3/10 | 47/161 |
| VomitingGastrointestinal disorders | 3/10 | 3/10 | 2/10 | 5/10 | 1/10 | 38/161 |
| Decreased appetiteMetabolism and nutrition disorders | 3/10 | 5/10 | 3/10 | 5/10 | 2/10 | 34/161 |
| ConstipationGastrointestinal disorders | 4/10 | 2/10 | 2/10 | 1/10 | 1/10 | 45/161 |
| DiarrhoeaGastrointestinal disorders | 3/10 | 4/10 | 2/10 | 3/10 | 2/10 | 41/161 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/10 | 3/10 | 1/10 | 0/10 | 2/10 | 23/161 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/10 | 1/10 | 0/10 | 4/10 | 2/10 | 3/161 |
Safety Analysis Set: all participants who received at least 1 dose of balstilimab.
| Age, Customized(Participants) | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 | Phase 2: Balstilimab Recommended Phase 2 Dose | Total |
|---|---|---|---|---|---|---|---|
| Adults (18-64 years) | 7 | 9 | 6 | 7 | 6 | 119 | 154 |
| From 65-84 years | 3 | 1 | 4 | 3 | 4 | 42 | 57 |
| Sex: Female, Male(Participants) | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 | Phase 2: Balstilimab Recommended Phase 2 Dose | Total |
|---|---|---|---|---|---|---|---|
| Female | 8 | 8 | 9 | 9 | 8 | 161 | 203 |
| Male | 2 | 2 | 1 | 1 | 2 | 0 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 | Phase 2: Balstilimab Recommended Phase 2 Dose | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 1 | 1 | 38 | 43 |
| Not Hispanic or Latino | 9 | 10 | 8 | 9 | 9 | 39 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 84 | 84 |
| Race/Ethnicity, Customized(Participants) | Phase 1: Balstilimab Dose 1 | Phase 1: Balstilimab Dose 2 | Phase 1: Balstilimab Dose 3 | Phase 1: Balstilimab Dose 4 | Phase 1: Balstilimab Dose 5 | Phase 2: Balstilimab Recommended Phase 2 Dose | Total |
|---|---|---|---|---|---|---|---|
| Asian | 0 | 3 | 1 | 1 | 1 | 1 | 7 |
| Black or African American | 2 | 1 | 0 | 0 | 0 | 2 | 5 |
| White | 8 | 6 | 9 | 9 | 9 | 72 | 113 |
| Not Reported (France) | 0 | 0 | 0 | 0 | 0 | 81 | 81 |
| Romanian | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Mixed | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Brown | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Jun 2022, 62 months.
Results were first posted in Jul 2025, 3 years 1 month after primary completion. A results delay was requested in Jun 2023.
Of 53 industry-sponsored phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 75. This study's 62 months is close to that.
Counting every sponsor, half of 81 studies reached it within 62 months; a quarter within 36 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Balstilimab